Last reviewed 2026-04-20 · How we verify

IL-7

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Nausea
• Constipation
• Headache
• Creatinine Increased
• Anemia
• Hyponatremia
• Chills
• Hypotension
• Hypoalbuminemia
• Alkaline Phosphatase Increased
• Vomiting

Key clinical trials

• Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) (PHASE2)
• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
• Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (PHASE1)
• NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
• A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia (PHASE1, PHASE2)
• Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (PHASE1)
• Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders (PHASE1)
• Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IL-7 CI brief — competitive landscape report
• IL-7 updates RSS · CI watch RSS
• National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI